Characterization of β2-Glycoprotein I Binding to Phospholipid Membranes

Mark F. Harper; Peter M. Hayes; Barry R. Lentz; Robert A. S. Roubey

doi:10.1055/s-0037-1615431

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(04): 610-614
DOI: 10.1055/s-0037-1615431

Rapid Communication

Schattauer GmbH

Characterization of β₂-Glycoprotein I Binding to Phospholipid Membranes

Authors

Mark F. Harper

¹From the Division of Rheumatology and Immunology, Department of Medicine
Peter M. Hayes

¹From the Division of Rheumatology and Immunology, Department of Medicine
Barry R. Lentz

²From the Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Robert A. S. Roubey

¹From the Division of Rheumatology and Immunology, Department of Medicine

Abstract

Summary

The plasma protein β₂-glycoprotein I (β₂-GPI) is a major target of autoantibodies in patients with the antiphospholipid syndrome. To understand the physiological function of β₂-GPI and its potential role in the pathophysiology of the antiphospholipid syndrome, the binding of β₂-GPI to phospholipid membranes was characterized. The interaction of β₂-GPI with unilamellar vesicles containing varying amounts of acidic phospholipids with phosphatidylcholine (PC) was measured at equilibrium via relative light scattering. Analysis of binding isotherms gave apparent K_d values ranging from approximately 5.0 to 0.5 μM over a range of 5-20 mol % anionic phospholipid. Inhibition of binding by increasing ionic strength and Ca²⁺ ions suggests that binding is primarily electrostatic. These data indicate that β₂-GPI binding to membranes with physiological anionic phospholipid content is relatively weak in comparison to plasma coagulation proteins, suggesting that β₂-GPI does not function as a physiological anticoagulant based on its phospholipid-binding properties.

Full Text

References

References
1 Matsuura E, Igarashi Y, Yasuda T, Koike T, Triplett DA. Anticardiolipin antibodies recognize β₂-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
2 Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize β₂-glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995; 154: 954-60.
3 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β₂-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-4.
4 Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and amino acid sequence of human beta-2-glycoprotein I. Biochem J 1991; 277: 387-91.
5 Mehdi H, Nunn M, Steel DM, Whitehead AS, Perez M, Walker L. et al. Nucleotide sequence and expression of the human gene encoding apolipo-protein H (β₂-glycoprotein I). Gene 1991; 108: 293-8.
6 Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ichikawa K, Yasuda T. et al. Molecular definition of human β₂-glycoprotein I (β₂-GPI) by cDNA cloning and inter-species differences of β₂-GPI in alteration of anticardiolipin binding. Int Immunol 1991; 3: 1217-21.
7 Kristensen T, Schousboe I, Boel E, Mulvihill EM, Hansen RR, Møller KB. et al. Molecular cloning and mammalian expression of human β₂-glyco-protein I cDNA. FEBS Lett 1991; 289: 183-6.
8 Reid KBM, Bentley DR, Campbell RD, Chung LP, Sim RB, Kristensen T. et al. Complement system proteins which interact with C3b or C4b: a superfamily of structurally related proteins. Immunol Today 1986; 7: 230-4.
9 Wurm H. β₂-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-5.
10 Polz E, Wurm H, Kostner GM. Investigations on β₂-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. J Biochem 1980; 11: 265-70.
11 Schousboe I, Rasmussen MS. The effect of β₂-glycoprotein I on the dextran sulfate and sulfatide activation of the contact system (Hageman factor system) in the blood coagulation. Int J Biochem 1988; 20: 787-92.
12 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β₂-glyco-protein I critical for lipid binding and anti-cardiolipin cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
13 Hunt J, Krilis S. The fifth domain of β₂-glycoprotein I contains a phospholipid binding site (cys281-cys288), and a region recognised by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
14 Steinkasserer A, Barlow PN, Willis AC, Kertesz Z, Campbell ID, Sim RB. et al. Activity, disulphide mapping and structural modelling of the fifth domain of human β₂-glycoprotein I. FEBS Lett 1992; 313: 193-7.
15 Kertesz Z, Yu B, Steinkasserer A, Haupt H, Benham A, Sim RB. Characterization of binding of human β₂-glycoprotein I to cardiolipin. Biochem J 1995; 310: 315-21.
16 Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interaction of apolipoprotein(a) with β₂-glycoprotein I mediated by the kringle IV domain. Blood 1997; 90: 1482-9.
17 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM. et al. Prothrombinase activity of human platelets is inhibited by β₂-glycoprotein I. Biochim Biophys Acta 1986; 884: 142-9.
18 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β₂-glycoprotien I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
19 Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β₂-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
20 Schousboe I. β₂-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
21 Nimpf J, Wurm H, Kostner GM. β₂-glycoprotein-I (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109-14.
22 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β₂-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-5.
23 Bancsi LFJMM, van der Linden IK, Bertina RM. β₂-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-53.
24 Brandt JT. Antibodies to β₂-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost 1993; 70: 598-602.
25 Nelsestuen GL, Lim TK. Equilibria involves in prothrombin- and blood-clotting factor X-membrane binding. Biochemistry 1977; 16: 4164-71.
26 Cutsforth GA, Whitaker RN, Hermans J, Lentz BR. A new model to describe extrinsic protein binding to phospholipid membranes of varying composition: application to human coagulation proteins. Biochemistry 1989; 28: 7453-61.
27 Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein I, a member of the lipocortin family. J Biol Chem 1989; 264: 7944-9.
28 Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson FD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-10.
29 Chen PS, Toribara TY, Warner H. Microdetermination of phosphorus. Anal Chem 1956; 28: 1756-8.
30 Lentz BR, McIntyre GF, Parks DJ, Yates JC, Massenburg D. Bilayer curvature and certain amphipaths promote poly(ethylene glycol)-induced fusion of dipalmitoylphosphatidylcholine unilamellar vesicles. Biochemistry 1992; 31: 2643-53.
31 Lentz BR, Zhou CM, Wu JR. Phosphatidylserine-containing membranes alter the thermal stability of prothrombin‘s catalytic domain: a differential scanninb calorimetric study. Biochemistry 1994; 33: 5460-8.
32 Koppaka V, Lentz BR. Binding of bovine factor Va to phosphatidylcholine membranes. Biophys J 1996; 70: 2930-7.
33 Cutsforth GA, Koppaka V, Krishnaswamy S, Wu JR, Mann KG, Lentz BR. Insights into the complex association of bovine factor Va with acidic-lipid-containing synthetic membranes. Biophys J 1996; 70: 2938-49.
34 Hagihara Y, Goto Y, Kato H, Yoshimura T. Role of the N- and C-terminal domains of bovine β₂-glycoprotein I in its interaction with cardiolipin. J Biochem 1995; 118: 129-36.
35 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” auto-antibodies. Blood 1994; 84: 2854-67.
36 Willems GM, Janssen MP, Pelsers MMAL, Comfurius P, Galli M, Zwaal RFA. et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-β₂-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
37 Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E. et al. Anti-β₂-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 1997; 99: 2260-8.
38 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79-86.
39 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-31.
40 Krishnaswamy S, Mann KG. The binding of factor Va to phospholipid vesicles. J Biol Chem 1988; 263: 5714-23.